Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajd.14199 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-in-Human clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein-Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic studies.
Clin Cancer Res
January 2025
The Wistar Institute, Philadelphia, PA, United States.
Purpose: A first-in-human phase one study was conducted in nasopharyngeal carcinoma (NPC) patients to assess the safety and tolerability of VK-2019, a small molecule selective inhibitor of Epstein-Barr virus Nuclear Antigen 1 (EBNA1).
Patients And Methods: Pharmacokinetic and pharmacodynamic studies, including circulating tumor EBV DNA plasma levels, were performed. Twenty-three patients received VK-2019 orally once daily at doses ranging from 60 to 1800 mg using an accelerated titration design, with cohort expansion at 1800 mg.
Based on the MaxEnt model the analysis of influencing factors and simulation of potential risk areas of human infection with avian influenza A (H7N9) in China.
Front Cell Infect Microbiol
January 2025
Faculty of Geography, Yunnan Normal University, Kunming, China.
Exposure to infected animals and their contaminated environments may be the primary cause of human infection with the H7N9 avian influenza virus. However, the transmission characteristics and specific role of various influencing factors in the spread of the epidemic are not clearly understood. Therefore, it is of great significance for scientific research and practical application to explore the influencing factors related to the epidemic.
View Article and Find Full Text PDFMolnupiravir is an antiviral medicine that induces lethal copying errors during SARS-CoV-2 RNA replication. Molnupiravir reduced hospitalization in one pivotal trial by 50% and had variable effects on reducing viral RNA levels in three separate trials. We used mathematical models to simulate these trials and closely recapitulated their virologic outcomes.
View Article and Find Full Text PDFPhylogenetic and Sequence Analyses of the Variable Region in the Glycoprotein Gene of the Respiratory Syncytial Virus Isolated from Iraqi Patients.
Malays J Med Sci
December 2024
Department of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Pulau Pinang, Malaysia.
Background: Respiratory syncytial virus (RSV) is a common aetiological agent that causes respiratory infections, especially among infants. Identifying circulating RSV genotypes is an essential strategy for understanding the spread of the virus in a certain area. Sequencing the variable regions of the attachment glycoprotein (G) gene of RSV is a quick and direct approach for identifying the genotypes.
View Article and Find Full Text PDFRNA viruses like SARS-CoV-2 have a high mutation rate, which contributes to their rapid evolution. The rate of mutations depends on the mutation type (e.g.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!